Metastatic Stage IV (D) Prostate Cancer

Combination Hormone Therapy Appears Safe and Effective in Reducing Testosterone in Metastatic Prostate Cancer (06-18-2014)

In a study presented at the 2014 American Society of Clinical Oncologists meeting, researchers reported that the use of two hormone blocking agents—Xtandi® (enzalutamide) and Zytiga® (abiraterone)—appeared safe and reduced testosterone levels in... Continue Reading

Xtandi Found to Delay Need for Chemotherapy in Metastatic Prostate Cancer Patients (06-16-2014)

In results of a phase III trial reported at the 2014 American Society of Clinical Oncologists, treatment with Xtandi® (enzalutamide) was found to significantly delay the need for chemotherapy in metastatic prostate cancer patients previously treated... Continue Reading

Taxotere Added to Hormone Therapy Improves Overall Survival by 13 Months in Metastatic Prostate Cancer Patients (06-3-2014)

In a study conducted by researchers at the Dana-Farber Cancer Institute, Taxotere® (docetaxel) administered with androgen-deprivation therapy to metastatic prostate cancer patients was found to extend overall survival by more than 13 months. The results... Continue Reading

Xtandi Shows Significant Benefit in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer (04-21-2014)

Xtandi® (enzalutamide) showed significant survival benefit in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according to the results of a study presented at the 2014 European Association of Urology (EAU) Congress in Stockholm,... Continue Reading

High Incidence of Many Complications after Surgery or Radiation for Prostate Cancer (02-27-2014)

Men who undergo surgery or radiation therapy for prostate cancer may face a variety of complications in addition to incontinence and erectile dysfunction—including high rates of hospitalization, urologic procedures, anal/rectal procedures, open surgeries,... Continue Reading

Xtandi Improves Survival in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer (02-19-2014)

Xtandi® (enzalutamide) improved survival and reduced the risk of radiographic progression in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according to the results of a study presented at the 2014 Genitourinary Cancers... Continue Reading

Zytiga Prolongs Time to Pain Progression (01-31-2014)

The addition of Zytiga® (abiraterone) to prednisone significantly delayed patient-reported pain progression and health-related quality-of-life deterioration compared with prednisone alone in chemotherapy-naive men with metastatic castration-resistant... Continue Reading

Xofigo Improves Bone and Pain in Prostate Cancer (10-14-2013)

Patients with hormone-refractory prostate cancer and bone metastases had significant improvement in skeletal- and pain-related outcomes when treated with Xofigo® (radium-223), according to the results of a study presented at the annual meeting of the... Continue Reading

Metformin May Improve Survival in Diabetic Men with Prostate Cancer (09-4-2013)

Diabetic men with prostate cancer lived significantly longer and were significantly less likely to die of prostate cancer when treated with metformin, an insulin-lowering drug, according to the results of a study published in Journal of Clinical Oncology. Prostate... Continue Reading

Xofigo Improves Survival in Metastatic, Hormone-Refractory Prostate Cancer (08-9-2013)

Xofigo® (radium-223) significantly improved overall survival in men with metastatic, hormone-refractory prostate cancer that has spread to bones (but not other organs), according to the results of a study published in the New England Journal of Medicine Prostate... Continue Reading

« Previous PageNext Page »